Will GSK’s share price spike on Zantac news be sustained?

GSK’s share price spiked on news of a settlement over Zantac, but other factors also mean it may continue to recover losses from its high this year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GSK’s (LSE: GSK) share price rose on Friday 23 June on news of a settlement over its Zantac drug. The terms of the settlement were confidential, although the company did not admit any liability. But that was not the point for the markets – the point was that it ended the uncertainty over the case. And the markets hate uncertainty.

Now the markets can refocus on the core investment proposition of GSK, which looks very good to me. Better still is that even with the rise on Friday, the stock is still down 7% from its year high. This means a possible bargain.

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALL3 Jan 202226 Jun 2023Zoom ▾Mar '22May '22Jul '22Sep '22Nov '22Jan '23Mar '23May '23May '22May '22Sep '22Sep '22Jan '23Jan '23May '23May '23www.fool.co.uk

AstraZeneca uncertainty may be beneficial

I hold shares in both GSK and AstraZeneca, the two main companies in the FTSE 100’s Medicine and Biotech sector. If I didn’t and wanted exposure to the sector, then I would probably plump for GSK now.

Should you invest £1,000 in Gsk right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Gsk made the list?

See the 6 stocks

The reason is, again, uncertainty. Specifically, according to several reports, AstraZeneca may spin off its lucrative China business. The listing of a separate unit in Hong Kong or mainland China is also rumoured to be an option.

To me, these are rumours only and are irrelevant. But many investors will be put off by the uncertainty they create. And this may well benefit GSK as the other main firm in the same FTSE 100 sector.

GSK has suffered in some respects in the past through comparison to its rival. This has mainly been due, in my opinion, to the disparity in new products pipelines between the two firms. AstraZeneca currently has 179 items in the pipeline, while GSK has 68. The key now, though, is that the latter does not have uncertainty surrounding its future, while AstraZeneca does.

Very promising products pipeline

It may have fewer new products in the pipeline than its rival, but they look good to me. One key area for it is respiratory medicine and, to this end, it bought Bellus Health in early April. It has a potential world-leading treatment for chronic coughs. This is expected to be a big seller through to 2031, adding to adjusted EPS from 2027.

Its Shingrix shingles vaccine also continues to perform strongly, generating £833m in revenues in Q1 2023. This compared to consensus analyst expectations of £829m.

GSK also affirmed its earlier guidance for increases in turnover, profit, and earnings per share (EPS) this year. Turnover is expected to rise by 6%-8%, adjusted operating profit by 10%-12%, and adjusted EPS by as much as 12%-15%.

Healthy dividend yields

The shares have also come with very healthy dividend yields in recent years. 2022 saw a dip to 3.1%, but it was 4% and 4.8% in the two previous years.  

There are risks for me in the share price, of course. Pharmaceutical companies spend much time and money on product development and if one fails then it is a huge setback. They are also vulnerable to legal action against them if products cause problematic side effects, as seen with Zantac.

I have maintained unbroken holdings in GSK for many years now and am happy to continue to do so. The shares have provided me with considerable gains in terms of price and dividends. I would buy the stock now, if I did not own it, to provide me with sustained long-term gains.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Simon Watkins has positions in AstraZeneca Plc and GSK. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Investing Articles

3 FTSE 100 shares that could make it rain dividends in 2025

Ben McPoland considers a trio of high-yield FTSE dividend stocks that are set to offer very attractive passive income this…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

On a P/E ratio of 6, is the Centrica share price a bargain?

The Centrica price-to-earnings ratio is in the mid-single digits. This writer weighs some pros and cons of adding the share…

Read more »

Investing Articles

2 top growth stocks to consider for 2025!

These growth stocks are expected to deliver more spectacular earnings increases in 2025. Is it time to consider loading up?

Read more »

Stack of one pound coins falling over
Investing Articles

Can this 10.8% yield from a FTSE 250 share last?

A well-known FTSE 250 share now has a dividend yield not far off 11%. Our writer digs into the business…

Read more »

Investing Articles

How to use a £20k ISA allowance to invest for passive income

The idea of enjoying some passive income in our old age can definitely be a realistic ambition, depending on how…

Read more »

Investing Articles

Down 95%, could the THG share price bounce back in 2025?

The THG share price has tanked in the past year -- and before, too. So will our writer buy in…

Read more »

US Stock

Prediction: AI stocks will outperform again in 2025 and Nvidia will hit $200

Over the last two years, Nvidia stock has soared on the back of AI. Ed Sheldon believes the stock, and…

Read more »

Elevated view over city of London skyline
Investing Articles

10.9%+ yield! Here’s my 2025-2027 M&G dividend forecast

Christopher Ruane explains why, although the M&G dividend yield already tops 10%, he's hopeful it could move even higher over…

Read more »